MS Speaks

Multiple Sclerosis => MS - RESEARCH AND NEWS => Topic started by: agate on October 19, 2017, 06:35:55 am

Title: (Abst.) Patient selection for trials
Post by: agate on October 19, 2017, 06:35:55 am
From PubMed, October 19, 2017:

Quote
Mult Scler. 2017 Oct;23(12):1636-1641.

Patient selection for trials

Wolinsky JS1.

Author information
1
Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.

The last several decades have witnessed considerable progress in our understanding of the pathogenesis, refining diagnostic criteria, and identifying therapies of value for modifying the course of relapsing forms of multiple sclerosis. While the pace of progress has lagged for those with progressive phase disease, this now seems to be changing.

This review considers those characteristics of patients with primary progressive multiple sclerosis that may contribute to phase 3 trial success and identifies some of the thorny issues that remain ahead. The larger of the studies conducted thus far have sequentially informed our understanding of "pure" primary progressive disease, and also challenge both phase 3 and especially phase 2 trial designs and participant selection for investigations going forward. This may have particular relevance for testing therapeutics directed at neuroprotection and repair in the face of ongoing progression regardless of trial participant categorization using current conventional disease phenotypes.

https://www.ncbi.nlm.nih.gov/pubmed/29041867 (https://www.ncbi.nlm.nih.gov/pubmed/29041867)